The interest in this pathway has gradually increased since the identification of two potent inhibitors, larotrectinib and entrectinib, with a wide spectrum of action and efficacy not only in NTRK altered cancer cells but also in cases where other altered genes are present, such as ALK or ROS1. This evidence concerns the gene ALK and cancer.